Using machine learning to predict radiation pneumonitis in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy

被引:74
|
作者
Valdes, Gilmer [1 ]
Solberg, Timothy D. [1 ]
Heskel, Marina [1 ]
Ungar, Lyle [2 ]
Simone, Charles B., II [1 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Comp & Informat Sci, 200 S 33Rd St, Philadelphia, PA 19104 USA
来源
PHYSICS IN MEDICINE AND BIOLOGY | 2016年 / 61卷 / 16期
关键词
radiation pneumonitis; stereotactic body radiation therapy (SBRT); non-small cell lung cancer; machine learning; Decision Trees; RUSBoost; Random Forests; DOSE-VOLUME HISTOGRAM; INDUCED PULMONARY TOXICITY; RADIOTHERAPY OUTCOMES; RISK;
D O I
10.1088/0031-9155/61/16/6105
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
To develop a patient-specific 'big data' clinical decision tool to predict pneumonitis in stage I non-small cell lung cancer (NSCLC) patients after stereotactic body radiation therapy (SBRT). 61 features were recorded for 201 consecutive patients with stage I NSCLC treated with SBRT, in whom 8 (4.0%) developed radiation pneumonitis. Pneumonitis thresholds were found for each feature individually using decision stumps. The performance of three different algorithms (Decision Trees, Random Forests, RUSBoost) was evaluated. Learning curves were developed and the training error analyzed and compared to the testing error in order to evaluate the factors needed to obtain a cross-validated error smaller than 0.1. These included the addition of new features, increasing the complexity of the algorithm and enlarging the sample size and number of events. In the univariate analysis, the most important feature selected was the diffusion capacity of the lung for carbon monoxide (DLCO adj%). On multivariate analysis, the three most important features selected were the dose to 15 cc of the heart, dose to 4 cc of the trachea or bronchus, and race. Higher accuracy could be achieved if the RUSBoost algorithm was used with regularization. To predict radiation pneumonitis within an error smaller than 10%, we estimate that a sample size of 800 patients is required. Clinically relevant thresholds that put patients at risk of developing radiation pneumonitis were determined in a cohort of 201 stage I NSCLC patients treated with SBRT. The consistency of these thresholds can provide radiation oncologists with an estimate of their reliability and may inform treatment planning and patient counseling. The accuracy of the classification is limited by the number of patients in the study and not by the features gathered or the complexity of the algorithm.
引用
下载
收藏
页码:6105 / 6120
页数:16
相关论文
共 50 条
  • [1] Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
    Aridgides, Paul
    Bogart, Jeffrey
    THORACIC SURGERY CLINICS, 2016, 26 (03) : 261 - +
  • [2] A DOSE-VOLUME ANALYSIS OF RADIATION PNEUMONITIS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIATION THERAPY
    Barriger, R. Bryan
    Forquer, Jeffrey A.
    Brabham, Jeffrey G.
    Andolino, David L.
    Shapiro, Ronald H.
    Henderson, Mark A.
    Johnstone, Peter A. S.
    Fakiris, Achilles J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01): : 457 - 462
  • [3] Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
    Shi, Shiming
    Zeng, Zhaochong
    Ye, Luxi
    Huang, Yan
    He, Jian
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2017, 16 (03) : 316 - 320
  • [4] Risk factors associated with symptomatic radiation pneumonitis after stereotactic body radiation therapy for stage I non-small cell lung cancer
    He, I.
    Zeng, Z.
    Shi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S102 - S102
  • [5] NTCP Model for Radiation Pneumonitis after Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer Patients
    Yao, H.
    Liu, Y.
    Jin, J. Y.
    Kong, F. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E716 - E717
  • [6] Amiodarone Use and Radiation Pneumonitis in Patients Undergoing Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer
    Agabalogun, T.
    Hassanzadeh, C. J.
    Caruthers, D.
    Huang, Y.
    Samson, P.
    Robinson, C. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E160 - E160
  • [7] Exploratory analysis using machine learning to predict for chest wall pain in patients with stage I non-small-cell lung cancer treated with stereotactic body radiation therapy
    Chao, Hann-Hsiang
    Valdes, Gilmer
    Luna, Jose M.
    Heskel, Marina
    Berman, Abigail T.
    Solberg, Timothy D.
    Simone, Charles B.
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2018, 19 (05): : 539 - 546
  • [8] Association of Lung Stereotactic Body Radiation Therapy Conformality Index and Posttreatment Radiation Pneumonitis in Early Stage Non-small Cell Lung Cancer
    Hutten, R.
    Surucu, M.
    Joyce, C.
    Alite, F., Jr.
    Stang, K.
    Small, C.
    Sethi, A.
    Emami, B.
    Harkenrider, M. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E464 - E464
  • [9] Stereotactic body radiation therapy for stage I medically operable non-small cell lung cancer
    Esengul Kocak Uzel
    Melisa Bagci Kilic
    Hasan Morcali
    Omer Uzel
    Scientific Reports, 13
  • [10] Stereotactic body radiation therapy for stage I medically operable non-small cell lung cancer
    Uzel, Esengul Kocak
    Kilic, Melisa Bagci
    Morcali, Hasan
    Uzel, Omer
    SCIENTIFIC REPORTS, 2023, 13 (01)